Adjuvant Immunotherapy after Curative Treatment for Hepatocellular Carcinoma

被引：24
|
作者：
Kudo, Masatoshi [1 ]
机构：
[1] Kindai Univ, Fac Med, Dept Gastroenterol & Hepatol, Osaka, Japan
来源：
LIVER CANCER | 2021年 / 10卷 / 05期
关键词：
Hepatocellular carcinoma; Nivolumab; Adjuvant immunotherapy; Anti-VEGF antibody; ATEZOLIZUMAB PLUS BEVACIZUMAB; DOUBLE-BLIND; RECURRENCE; RESECTION; ABLATION;
D O I：
10.1159/000518584
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
收藏
页码：399 / 403
页数：5
相关论文
共 50 条
  • [31] Shanghai Score: A Prognostic and Adjuvant Treatment-evaluating System Constructed for Chinese Patients with Hepatocellular Carcinoma after Curative Resection
    Sun, Hui-Chuan
    Xie, Lu
    Yang, Xin-Rong
    Li, Wei
    Yu, Jian
    Zhu, Xiao-Dong
    Xial, Yong
    Zhang, Ti
    Xu, Yang
    Hu, Bo
    Du, Li-Ping
    Zeng, Ling-Yao
    Ouyang, Jian
    Zhang, Wei
    Song, Tian-Qiang
    Li, Qiang
    Shil, Ying-Hong
    Zhou, Jian
    Qiu, Shuang-Jian
    Liu, Qian
    Li, Yi-Xue
    Tang, Zhao-You
    Shyr, Yu
    Shen, Feng
    Fan, Jia
    CHINESE MEDICAL JOURNAL, 2017, 130 (22) : 2650 - +
  • [32] Long-term prognosis and management of hepatocellular carcinoma after curative treatment
    Nishida, Naoshi
    CLINICAL AND MOLECULAR HEPATOLOGY, 2020, 26 (04) : 480 - 483
  • [33] A randomised controlled trial of meloxicam, a Cox-2 inhibitor, to prevent hepatocellular carcinoma recurrence after initial curative treatment
    Takami, Yuko
    Eguchi, Susumu
    Tateishi, Masaki
    Ryu, Tomoki
    Mikagi, Kazuhiro
    Wada, Yoshiyuki
    Saitsu, Hideki
    HEPATOLOGY INTERNATIONAL, 2016, 10 (05) : 799 - 806
  • [34] Adjuvant interferon therapy after curative therapy for hepatocellular carcinoma (HCC): A meta-regression approach
    Shen, Ying-Chun
    Hsu, Chiun
    Chen, Li-Tzong
    Cheng, Chia-Chi
    Hu, Fu-Chang
    Cheng, Ann-Lii
    JOURNAL OF HEPATOLOGY, 2010, 52 (06) : 889 - 894
  • [35] Adjuvant Transarterial Chemoembolization after Curative Resection of Hepatocellular Carcinoma: A Non-Randomized Comparative Study
    Xi, Tao
    Lai, Eric C. H.
    Min, An-ru
    Shi, Le-hua
    Wu, Dong
    Xue, Feng
    Wang, Kui
    Yan, Zhenlin
    Xia, Yong
    Shen, Feng
    Lau, Wan Yee
    Wu, Meng-chao
    HEPATO-GASTROENTEROLOGY, 2012, 59 (116) : 1198 - 1203
  • [36] Treatment of inoperable hepatocellular carcinoma with immunotherapy
    Tighe, Sean P.
    Iqbal, Umair
    Fernandes, Christopher T.
    Ahmed, Aijaz
    BMJ CASE REPORTS, 2019, 12 (07)
  • [37] Management of sub-centimeter recurrent hepatocellular carcinoma after curative treatment: Current status and future
    Lee, Min Woo
    Lim, Hyo Keun
    WORLD JOURNAL OF GASTROENTEROLOGY, 2018, 24 (46) : 5215 - 5222
  • [38] Natural killer cell activity is a risk factor for the recurrence risk after curative treatment of hepatocellular carcinoma
    Lee, Han Ah
    Goh, Hyun Gil
    Lee, Young-Sun
    Jung, Young Kul
    Kim, Ji Hoon
    Yim, Hyung Joon
    Lee, Min-Goo
    An, Hyunggin
    Jeen, Yoon Tae
    Yeon, Jong Eun
    Byun, Kwan Soo
    Seo, Yeon Seok
    BMC GASTROENTEROLOGY, 2021, 21 (01)
  • [39] Targeted therapy or immunotherapy? Optimal treatment in hepatocellular carcinoma
    Contratto, Merly
    Wu, Jennifer
    WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2018, 10 (05) : 108 - 114
  • [40] Management of sub-centimeter recurrent hepatocellular carcinoma after curative treatment:Current status and future
    Min Woo Lee
    Hyo Keun Lim
    World Journal of Gastroenterology, 2018, (46) : 5215 - 5222
12345